{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5(1)"],"submitter":["de Assis LVM"],"pubmed_abstract":["The search for new therapeutical targets for cutaneous melanoma and other cancers is an ongoing task. We expanded this knowledge by evaluating whether opsins, light- and thermo-sensing proteins, could display tumor-modulatory effects on melanoma cancer. Using different experimental approaches, we show that melanoma cell proliferation is slower in the absence of Opn4, compared to Opn4<sup>WT</sup> due to an impaired cell cycle progression and reduced melanocyte inducing transcription factor (Mitf) expression. In vivo tumor progression of Opn4<sup>KO</sup> cells is remarkably reduced due to slower proliferation, and higher immune system response in Opn4<sup>KO</sup> tumors. Using pharmacological assays, we demonstrate that guanylyl cyclase activity is impaired in Opn4<sup>KO</sup> cells. Eva"],"journal":["Communications biology"],"pagination":["461"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9106662"],"repository":["biostudies-literature"],"pubmed_title":["Melanopsin (Opn4) is an oncogene in cutaneous melanoma."],"pmcid":["PMC9106662"],"pubmed_authors":["Camara NOS","Menck CFM","Mendes D","Castrucci AML","Lacerda JT","Silva MM","Moraes MN","Kinker GS","de Assis LVM","Dominguez-Amorocho OA"],"additional_accession":[]},"is_claimable":false,"name":"Melanopsin (Opn4) is an oncogene in cutaneous melanoma.","description":"The search for new therapeutical targets for cutaneous melanoma and other cancers is an ongoing task. We expanded this knowledge by evaluating whether opsins, light- and thermo-sensing proteins, could display tumor-modulatory effects on melanoma cancer. Using different experimental approaches, we show that melanoma cell proliferation is slower in the absence of Opn4, compared to Opn4<sup>WT</sup> due to an impaired cell cycle progression and reduced melanocyte inducing transcription factor (Mitf) expression. In vivo tumor progression of Opn4<sup>KO</sup> cells is remarkably reduced due to slower proliferation, and higher immune system response in Opn4<sup>KO</sup> tumors. Using pharmacological assays, we demonstrate that guanylyl cyclase activity is impaired in Opn4<sup>KO</sup> cells. Eva","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2025-04-19T16:21:22.749Z","creation":"2025-04-19T16:21:22.749Z"},"accession":"S-EPMC9106662","cross_references":{"pubmed":["35562405"],"doi":["10.1038/s42003-022-03425-6"]}}